Your browser doesn't support javascript.
loading
A synthetic heparinoid blocks Tau aggregate cell uptake and amplification.
Stopschinski, Barbara E; Thomas, Talitha L; Nadji, Sourena; Darvish, Eric; Fan, Linfeng; Holmes, Brandon B; Modi, Anuja R; Finnell, Jordan G; Kashmer, Omar M; Estill-Terpack, Sandi; Mirbaha, Hilda; Luu, Hung S; Diamond, Marc I.
Affiliation
  • Stopschinski BE; Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390; Department of Neurology, RWTH University Aachen, 52074 Aachen, Germany.
  • Thomas TL; Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390.
  • Nadji S; PharmaRen Discovery LLC, Berkeley, Missouri 63134-3115.
  • Darvish E; PharmaRen Discovery LLC, Berkeley, Missouri 63134-3115.
  • Fan L; Shanghai Acana Pharmtech Co. Ltd., Berkeley, Missouri 63134-3115.
  • Holmes BB; Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390; Department of Neurology, University of California, San Francisco, California 94143.
  • Modi AR; Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390.
  • Finnell JG; Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390.
  • Kashmer OM; Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390.
  • Estill-Terpack S; Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390.
  • Mirbaha H; Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390.
  • Luu HS; Department of Pathology, Children's Health, University of Texas Southwestern Medical Center, Dallas, Texas 75390.
  • Diamond MI; Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390. Electronic address: marc.diamond@utsouthwestern.edu.
J Biol Chem ; 295(10): 2974-2983, 2020 03 06.
Article in En | MEDLINE | ID: mdl-31974166
Tau aggregation underlies neurodegeneration in Alzheimer's disease and related tauopathies. We and others have proposed that transcellular propagation of pathology is mediated by Tau prions, which are ordered protein assemblies that faithfully replicate in vivo and cause specific biological effects. The prion model predicts the release of aggregates from a first-order cell and subsequent uptake into a second-order cell. The assemblies then serve as templates for their own replication, a process termed "seeding." We have previously observed that heparan sulfate proteoglycans on the cell surface mediate the cellular uptake of Tau aggregates. This interaction is blocked by heparin, a sulfated glycosaminoglycan. Indeed, heparin-like molecules, or heparinoids, have previously been proposed as a treatment for PrP prion disorders. However, heparin is not ideal for managing chronic neurodegeneration, because it is difficult to synthesize in defined sizes, may have poor brain penetration because of its negative charge, and is a powerful anticoagulant. Therefore, we sought to generate an oligosaccharide that would bind Tau and block its cellular uptake and seeding, without exhibiting anticoagulation activity. We created a compound, SN7-13, from pentasaccharide units and tested it in a range of assays that measured direct binding of Tau to glycosaminoglycans and inhibition of Tau uptake and seeding in cells. SN7-13 does not inhibit coagulation, binds Tau with low nanomolar affinity, and inhibits cellular Tau aggregate propagation similarly to standard porcine heparin. This synthetic heparinoid could facilitate the development of agents to treat tauopathy.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tau Proteins / Heparin, Low-Molecular-Weight Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Biol Chem Year: 2020 Document type: Article Affiliation country: Germany Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tau Proteins / Heparin, Low-Molecular-Weight Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Biol Chem Year: 2020 Document type: Article Affiliation country: Germany Country of publication: United States